CTOs on the Move

Lasergen

www.lasergen.com

 
Lasergen is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation sequencing has led to a number of key discoveries resulting in both game-changing sequencing chemistry (Lightning Terminators™) and a more accurate sequencing platform. While focusing on the development of current cutting-edge technology, our continued drive for innovation and extensive sequencing knowledge allows us to rapidly evolve and keep pace with fast-changing advances in the sequencing industry.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Lasergen raised $80M on 03/07/2016

Similar Companies

Spenco Medical Corporation

"Cutting Edge medical is owned and operated by an authorized distributer for SPENCO located in Central New York , NY . SPENCO Medical Corporation was incorperated in 1967 with one goal - "" to provide customers with unique, marketable products and"

VisCardia

VisCardia Inc is a privately held medical device company in Portland Oregon developing a novel chronic heart failure therapy. Our proprietary implantable system uses the patient’s own thoracic musculature to improve cardiac filling and output.

CandG Technologies

C&G Technologies is a Jeffersonville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quantel Medical

Quantel Medical Inc. is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSig

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.